This increase from the previous estimate of 92,000 patients underscores the company's continued dominance in the CF market. Vertex has also made strides in gene therapy with the launch of CASGEVY.

H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on Tenaya Therapeutics Inc (NASDAQ:TNYA), with a price target of $18.00. This aligns with the strong overall analyst consensus, as ...

CHARLESTOWN, Mass., Feb. 04, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: SLDB) (the “Company”), a life sciences company developing ...

International collaborations, refined gene-editing protocols, and targeted immunologic maneuvers keep the cancer gene therapy ...

Health systems across the country are making it easier for primary care clinicians to order genetic tests for patients who ...

Tennant has a little-known genetic condition that means he was born with six toes on his right feet. There had been ...

In an interview with THE WEEK, Professor Chuan He, lead researcher at the University of Chicago, talks about the new findings ...

Scientists at UC San Francisco have pioneered a groundbreaking approach to fighting cancer using engineered fat cells. By ...

Republican Rep. Brandon Shippy wants to put a moratorium on mRNA vaccines, based on his ignorance about them. | Opinion ...

Chief Scientific Officer Yoshitsugu Shitaka, Ph.D., won’t be so lucky. Astellas intends to create the new role of Chief ...

Akribion Therapeutics emerges from stealth with €8 million in seed funding to develop a novel cancer RNA-guided approach ...

The California Institute for Regenerative Medicine has awarded a $6 million grant to USC investigators pioneering a new first ...